Biotech Bispecifics player Abpro teams up with China’s NJCTTQ in biobucks deal worth up to $4B

Abpro is partnering with China-based NJCTTQ to develop new bispecific antibodies using its antibody discovery platform. Under the agreement, Abpro could collect up to $4 billion, which includes $60 million in “near-term R&D funding,” as well as milestone payments and royalties.